PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate

benzinga.com/25/05/45669058/pepgen-abandons-duchenne-program-shifts-spotlight-to-another-rare-disease-candidate

PepGen Inc. (NASDAQ:PEPG) announced on Wednesday that it will focus on advancing its myotonic dystrophy type 1 (DM1) program, currently in Phase 2 clinical development.
The company voluntarily discontinued the development of PGN-EDO51 and intends to wind down all Duchenne muscular…

This story appeared on benzinga.com, 2025-05-29 13:19:53.
The Entire Business World on a Single Page. Free to Use →